Mechanism Unearthed for Carfilzomib-Induced Reticulocytosis in Myeloma
Irreversible proteasome inhibitor carfilzomib appears to cause reticulocytosis in multiple myeloma by inhibiting terminal erythroid maturation.
Multiple Myeloma
Nelfinavir Plus Lenalidomide, Dexamethasone Improves Response in Lenalidomide-Refractory Multiple Myeloma
Results of a phase 1/2 trial demonstrated the efficacy of nelfinavir in combination with lenalidomide and dexamethasone for lenalidomide-refractory MM.
Real-World Insight on Patients With Multiple Myeloma: Results Drawn From a Large Health Plan
A retrospective cohort study identified real-world epidemiology, treatment patterns, and survival outcomes in patients with multiple myeloma in Israel.
Knowing the Appropriateness of Running Noninferiority Trials in Oncology
Researches took a critical look at noninferiority trials and determined that when a new intervention is “not worse,” the possibility exists that it is not better, either.
Salvage Therapy Does Not Up Survival for Progressive Myeloma
Deepening of response through salvage therapy not linked to improved progression-free, overall survival.
A Simple Frailty Score Helped Predict Outcomes in Multiple Myeloma
The scoring system could be incorporated into future trials in elderly patients, authors said.
New DARZALEX® (Daratumumab) Combination Expands Options for Use in Newly Diagnosed, Transplant Ineligible Multiple Myeloma Patients
Combination therapy has become a common way to treat many cancers, as the complexity presented by certain types requires a variety of therapies to attack it.
Suboptimal Implementation of Supportive Care in Older Patients With Multiple Myeloma
Factors associated with poor adherence to specific guideline-recommended supportive care measures involved patient race and site of care.
Selinexor-Dexamethasone Induced Responses in Triple-Refractory Myeloma
Responses were seen in patients who have few remaining treatment options.
Tapping Into the Therapeutic Expertise of High-Volume Cancer Centers
Researchers examine how patient outcomes could be affected if patients were to receive systemic drug treatment at dedicated cancer centers versus at community health systems.
Next post in General Oncology
